| Trial ID: | L0475 |
| Source ID: | NCT00664066
|
| Associated Drug: |
Dynepo (Epoetin Delta)
|
| Title: |
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
|
| Acronym: |
DELFT
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00664066/results
|
| Conditions: |
Anemia|Kidney Diseases|Renal Failure, Chronic|Kidney Failure, Chronic
|
| Interventions: |
DRUG: DYNEPO (epoetin delta)
|
| Outcome Measures: |
Primary: Assess the Incidence and Severity of All Predefined Cardiovascular Events in Subjects Treated With Dynepo, This study was terminated on July 31, 2008 as a result of a decision by Shire Pharmaceutical to permanently cease marketing Dynepo and withdraw the Marketing Authorisation. The decision was for commercial reasons, it was not the result of any safety signal., up to 3 years |
|
| Sponsor/Collaborators: |
Sponsor: Shire
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
3
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-04-25
|
| Completion Date: |
2008-07-30
|
| Results First Posted: |
2009-09-28
|
| Last Update Posted: |
2021-06-25
|
| Locations: |
Nephrologische Zentrum Villingen-Schwenningen, Villingen - Schwenningen, Baden-Württemberg, 78054, Germany|Hanse-Klinikum Stralsund, Stralsund, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00664066
|
